Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 1/2 1

Status

Unknown 2Completed 2

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Other solid neoplasm 1

Conditions

Advanced Breast Cancer 2Solid Tumor, Adult 1Breast Neoplasms 1

Interventions

Cisplatin 3193Cyclophosphamide 3187Carboplatin 2968Radiotherapy 2784Paclitaxel 2716Gemcitabine 2569pembrolizumab 2378Bevacizumab 2206Docetaxel 2196Fluorouracil 1848Capecitabine 1828Oxaliplatin 1738Dexamethasone 1604Nivolumab 1580Doxorubicin 1501Rituximab 1487Magnetic Resonance Spectroscopy 1382Etoposide 1345Irinotecan 1245Leucovorin 1222Drug Therapy 1202Cytarabine 1130Pemetrexed 1074fludarabine 1056Specimen Handling 1009Vincristine 964Cetuximab 943Prednisone 940Trastuzumab 940Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
FCN-437c × Clear all
NCT06290466 2024-03-04

Clinical Study on Pharmacokinetics of FCN-437c Capsule and Its Effect on QT Interval in Healthy Subjects

Ahon Pharmaceutical Co., Ltd.

Phase 1 Completed
18 enrolled
Breast

Advanced Breast Cancer

NCT05439499 2022-07-06

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Ahon Pharmaceutical Co., Ltd.

Phase 3 Unknown
434 enrolled
Breast

Advanced Breast Cancer

NCT03951116 2022-03-16

FCN-437c

Fochon Pharmaceuticals, Ltd.

Phase 1 Completed
22 enrolled
Other solid neoplasm

Solid Tumor, Adult

NCT04488107 2020-07-27

Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c

Ahon Pharmaceutical Co., Ltd.

Phase 1/2 Unknown
78 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡